High plasminogen activator inhibitor type 2 expression is a hallmark of scleroderma fibroblasts in vitro

Experimental Dermatology

Volumn 13, Issue 11, 2004, Pages 708-714

  Kessler Becker, Daniela ^a   Smola, Sigrun ^a   Krieg, Thomas ^a   Eckes, Beate ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Fibroblast; Microarray; Protease inhibitor; Systematic scleroderma

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; CYTOKINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 2; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; NORTHERN BLOTTING; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; RNA ISOLATION; SENSITIVITY ANALYSIS; SKIN BIOPSY; SYSTEMIC SCLEROSIS; WESTERN BLOTTING;

ADULT; BIOPSY; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLASTS; GLYCOSYLATION; HUMANS; MALE; MICROSCOPY, FLUORESCENCE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 2; RECEPTORS, INTERLEUKIN-1; RNA; RNA, MESSENGER; SCLERODERMA, LOCALIZED; SCLERODERMA, SYSTEMIC; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 8344261570     PISSN: 09066705     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0906-6705.2004.00222.x     Document Type: Article

References (35)

1. Kissin E Y, Korn J H. Fibrosis in scleroderma. Rheum Dis Clin North Am 2003: 29: 351-369.
2. Krieg T, Meurer M. Systemic scleroderma. Clinical and pathophysiologic aspects. J Am Acad Dermatol 1988: 18: 457-481.
3. Yamamoto T, Takagawa S, Katayama I, Nishioka K. Anti-sclerotic effect of transforming growth factor-beta antibody in a mouse model of bleomycin-induced scleroderma. Clin Immunol 1999: 92: 6-13.
4. LeRoy E C. Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblast. J Clin Invest 1974: 54: 880-889.
5. LeRoy E C. The control of fibrosis in systemic sclerosis: a strategy involving extracellular matrix, cytokines, and growth factors. J Dermatol 1994: 21: 1-4.
6. Jelaska A, Arakawa M, Broketa G, Korn J H. Heterogeneity of collagen synthesis in normal and systemic sclerosis skin fibroblasts. Increased proportion of high collagen-producing cells in systemic sclerosis fibroblasts. Arthritis Rheum 1996: 39: 1338-1346.
7. Yamakage A, Kikuchi K, Smith E A, LeRoy E C, Trojanowska M. Selective upregulation of platelet-derived growth factor alpha receptors by transforming growth factor beta in scleroderma fibroblasts. J Exp Med 1992: 175: 1227-1234.
8. Kawakami T, Ihn H, Xu W, Smith E, LeRoy C, Trojanowska M. Increased expression of TGF-beta receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-beta signaling to scleroderma phenotype. J Invest Dermatol 1998: 110: 47-51.
9. Kawaguchi Y, Hara M, Wright T M. Endogenous IL-1 alpha from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. J Clin Invest 1999: 103: 1253-1260.
10. Takeda K, Hatamochi A, Ueki H, Nakata M, Oishi Y. Decreased collagenase expression in cultured systemic sclerosis fibroblasts. J Invest Dermatol 1994: 103: 359-363.
11. Strehlow D, Jelaska A, Strehlow K, Korn J H. A potential role for protease nexin 1 overexpression in the pathogenesis of scleroderma. J Clin Invest 1999: 103: 1179-1190.
12. Scott R W, Bergman B L, Bajpai A et al. Protease nexin. Properties and a modified purification procedure. J Biol Chem 1995: 260: 7029-7034.
13. Kessler D, Dethlefsen S, Haase I et al. Fibroblasts in mechanically stressed collagen lattices assume a "synthetic" phenotype. J Biol Chem 2001: 276: 36575-36585.
14. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003: 113: 685-700.
15. Grotendorst G R, Connective tissue growth factor. a mediator of TGF-beta action on fibroblasts. Cytokine Growth Factor Rev 1997: 8: 171-179.
16. Chiquet M, Flück M. Early responses to mechanical stress: from signals at the cell surface to altered gene expression. In: Storey K B, Storey J M, eds. Protein adaptations and signal transduction. Amsterdam: Elsevier Science B.V, 2001: 97-110.
17. Kruithof E K, Baker M S, Bunn C L. Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood 1995: 86: 4007-4024.
18. Dear A E, Medcalf R L. The cellular and molecular biology of plasminogen activator inhibitor type-2. Fibrinolysis 1995: 9: 321-330.
19. Mikus P, Ny T. Intracellular polymerization of the serpin plasminogen activator inhibitor type 2. J Biol Chem 1996: 271: 10048-10053.
20. Dickinson J L, Norris B J, Jensen P H, Antalis T M. The C-D interhelical domain of the serpin plasminogen activator inhibitor-type 2 is required for protection from TNF-alpha induced apoptosis. Cell Death Differ 1998: 5: 163-171.
21. Dougherty K M, Pearson J M, Yang A Y, Westrick R J, Baker M S, Ginsburg D. The plasminogen activator inhibitor-2 gene is not required for normal murine development or survival. Proc Natl Acad Sci USA 1999: 96: 686-691.
22. Schleuning W D, Medcalf R L, Hession C, Rothenbuhler R, Shaw A, Kruithof E K. Plasminogen activator inhibitor 2: regulation of gene transcription during phorbol ester-mediated differentiation of U-937 human histiocytic lymphoma cells. Mol Cell Biol 1987: 7: 4564-4567.
23. Carlson S G, Fawcett T W, Bartlett J D, Bernier M, Holbrook N J. Regulation of the C/EBP-related gene gadd153 by glucose deprivation. Mol Cell Biol 1993: 13: 4736-4744.
24. Subcommittee for scleroderma criteria of the American Rheumatism Association. Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1990: 23: 581-590.
25. LeRoy E C, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis). Classification, subsets and pathogenesis. J Rheumatol 1988: 15: 202-205.
26. Iyer V R, Eisen M B, Ross D T et al. The transcriptional program in the response of human fibroblasts to serum. Science 1999: 283: 83-87.
27. Kumar S, Baglioni C. Protection from tumor necrosis factor-mediated cytolysis by overexpression of plasminogen activator inhibitor type-2. J Biol Chem 1991: 266: 20960-20964.
28. Hamilton J A, Wojta J, Gallichio M, McGrath K, Filonzi E L. Contrasting effects of transforming growth factor-beta and IL-1 on the regulation of plasminogen activator inhibitors in human synovial fibroblasts. J Immunol 1993: 151: 5154-5161.
29. Michel J B, Quertermous T, Modulation of mRNA levels for urinary- and tissue-type plasminogen activator and plasminogen activator inhibitors 1 and 2 in human fibroblasts by interleukin 1. J Immunol 1989: 143: 890-895.
30. Kessler-Becker D, Krieg T, Eckes B. Expression of pro-inflammatory markers by human dermal fibroblasts in a three-dimensional culture model is mediated by an autocrine IL-1 loop. Biochem J 2004: 379: 351-358.
31. Mitchell H, Bolster M B, LeRoy E C. Scleroderma and related conditions. Med Clin North Am 1997: 81: 129-149.
32. Chiquet M. Regulation of extracellular matrix gene expression by mechanical stress. Matrix Biol 1999: 18: 417-426.
33. Kulozik M, Hogg A, Lankat-Buttgereit B, Krieg T, Co-localization of transforming growth factor beta 2 with alpha 1(I) procollagen mRNA in tissue sections of patients with systemic sclerosis. J Clin Invest 1990: 86: 917-922.
34. Ludwicka A, Ohba T, Trojanowska M et al. Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma. J Rheumatol 1995: 22: 1876-1883.
35. Strehlow D R. The promise of transcription profiling for understanding the pathogenesis of scleroderma. Curr Rheumatol Rep 2000: 2: 506-511.